TABLE 2

Effect of rosiglitazone on plasma fatty acid composition

Triglycerides
NEFAs
PlaceboRosiglitazonePPlaceboRosiglitazoneP
14:02.22 ± 1.01.71 ± 0.40.181.49 ± 0.71.64 ± 0.50.46
16:029.1 ± 4.926.3 ± 1.80.1024.6 ± 2.624.2 ± 1.70.59
16:1n-74.68 ± 1.34.87 ± 1.10.233.61 ± 1.04.0 ± 1.00.19
18:03.5 ± 0.83.0 ± 0.40.1413.8 ± 1.813.6 ± 2.10.74
18:1n-937.8 ± 8.436.5 ± 6.10.5440.6 ± 3.242.0 ± 4.10.18
18:2n-617.1 ± 5.521.5 ± 6.70.1013.0 ± 2.811.8 ± 4.10.48
18:3n-60.42 ± 0.30.43 ± 0.30.700.35 ± 0.20.41 ± 0.40.24
18:3n-31.29 ± 0.51.19 ± 0.40.531.25 ± 0.41.14 ± 0.60.46
20:3n-60.33 ± 0.100.39 ± 0.090.070.27 ± 0.20.20 ± 0.150.28
20:4n-61.16 ± 0.31.71 ± 0.70.0020.94 ± 0.21.00 ± 0.20.61
20:5n-30.46 ± 0.20.65 ± 0.40.08NDND
22:5n-30.39 ± 0.20.5 ± 0.40.21NDND
22:6n-30.83 ± 0.51.2 ± 1.10.19NDND
PS-ratio0.65 ± 0.20.90 ± 0.20.03ND*ND*
  • Data are means of molar proportions (%) ± SD. P values are differences within groups using a paired t test or Wilcoxon signed-rank test (n = 10).

  • *

    * Because several long-chain polyunsaturated fatty acids were nondetectable, the P/S ratio was not calculated for NEFAs.